Neurocognitive Disorder Due to Vascular Disease: Symptoms, Causes, Diagnosis, and Treatment

Neurocognitive disorder due to vascular disease — commonly known as vascular dementia or vascular cognitive impairment — is a decline in cognitive functioning caused by conditions that damage blood vessels in the brain, reducing or blocking blood flow to brain tissue. When neurons are deprived of oxygen and nutrients due to compromised cerebrovascular circulation, they become injured or die, leading to measurable deficits in thinking, memory, reasoning, and other cognitive domains.

The DSM-5-TR classifies this condition under the broader category of neurocognitive disorders and distinguishes between two severity levels:

• Major Neurocognitive Disorder Due to Vascular Disease: Significant cognitive decline from a previous level of functioning that interferes with independence in everyday activities. This corresponds to what is traditionally called vascular dementia.
• Mild Neurocognitive Disorder Due to Vascular Disease: Modest cognitive decline that does not interfere with the capacity for independence in daily activities, though the individual may need to exert greater effort or use compensatory strategies. This is roughly equivalent to vascular mild cognitive impairment (vascular MCI).

Vascular neurocognitive disorder is the second most common cause of dementia after Alzheimer's disease, accounting for approximately 15–20% of dementia cases worldwide. However, many experts believe this figure underestimates the true burden because vascular pathology frequently coexists with Alzheimer's pathology — a condition referred to as mixed dementia. Prevalence increases sharply with age, and estimates from the National Institute on Aging suggest that vascular contributions to cognitive impairment are present in as many as 40–50% of individuals with dementia when autopsy data are considered.

Unlike Alzheimer's disease, which typically follows a gradual, insidious decline, vascular neurocognitive disorder can present with a more variable course depending on the nature and location of the cerebrovascular damage. This distinction has important implications for prevention, treatment, and prognosis.

The symptoms of vascular neurocognitive disorder depend on which areas of the brain have been affected by vascular damage. Unlike Alzheimer's disease, where memory loss is often the earliest and most prominent symptom, vascular neurocognitive disorder frequently presents first with impairments in executive functioning, processing speed, and attention.

Core cognitive symptoms include:

• Slowed thinking and processing speed: Tasks that were once handled quickly now take considerably longer. The person may appear mentally sluggish or have difficulty keeping up with conversations.
• Executive dysfunction: Difficulty with planning, organizing, sequencing tasks, problem-solving, and abstract reasoning. This is often the hallmark feature, particularly in subcortical vascular disease.
• Attention and concentration deficits: Trouble sustaining focus, shifting attention between tasks, or managing multiple demands at once.
• Memory impairment: While memory is often affected, the pattern typically differs from Alzheimer's. Individuals may have difficulty retrieving stored information but perform better when given cues or recognition prompts, suggesting the information was encoded but is hard to access.
• Language difficulties: Word-finding problems, reduced verbal fluency, or difficulty following complex instructions.
• Visuospatial deficits: Difficulty judging distances, navigating familiar environments, or copying figures.

Behavioral and psychological warning signs include:

• Apathy and loss of motivation: A marked reduction in initiative, emotional responsiveness, and engagement with previously enjoyed activities. This is one of the most common neuropsychiatric features.
• Depression: Depressive symptoms occur in approximately 30–50% of individuals with vascular cognitive impairment and may precede or accompany cognitive decline.
• Emotional lability: Sudden, uncontrollable episodes of laughing or crying that are disproportionate to the situation — sometimes called pseudobulbar affect.
• Irritability and personality changes: Increased frustration, short temper, or social withdrawal.

Physical and neurological signs may include:

• Gait disturbances — a slow, shuffling, or unsteady walk
• Urinary urgency or incontinence (particularly in subcortical vascular disease)
• Focal neurological deficits such as one-sided weakness, speech difficulties, or visual field loss (especially following a stroke)
• Psychomotor slowing — reduced speed and coordination of movements

A particularly notable clinical pattern is "stepwise" decline, where cognitive functioning deteriorates in noticeable, sudden drops — often corresponding to discrete cerebrovascular events — rather than the smooth, gradual decline typical of Alzheimer's disease. However, this stepwise pattern is more characteristic of multi-infarct dementia and is not universal; subcortical small vessel disease often produces a more insidious, gradually progressive course that can closely mimic Alzheimer's disease.

Vascular neurocognitive disorder results from cerebrovascular disease — conditions that damage or obstruct blood vessels supplying the brain. Several distinct vascular mechanisms can produce cognitive impairment, and they frequently overlap:

Major cerebrovascular causes:

• Large vessel strokes (multi-infarct dementia): Multiple cortical or subcortical infarcts caused by thrombosis, embolism, or atherosclerosis of large cerebral arteries. A single stroke in a strategically important brain region (such as the thalamus, angular gyrus, or hippocampus) can also cause significant cognitive impairment — referred to as strategic infarct dementia.
• Small vessel disease: Chronic damage to small penetrating arteries and arterioles in the brain, leading to lacunar infarcts (small, deep brain infarcts) and diffuse white matter lesions (leukoaraiosis). This is the most common substrate of vascular cognitive impairment and is strongly associated with hypertension and diabetes.
• Hemorrhagic stroke: Intracerebral hemorrhage (bleeding within the brain) can destroy tissue directly and cause secondary damage through increased intracranial pressure and inflammation.
• Cerebral amyloid angiopathy: A condition in which amyloid protein deposits in the walls of small and medium-sized cerebral blood vessels, making them fragile and prone to microbleeds and lobar hemorrhages. This condition frequently coexists with Alzheimer's pathology.
• Chronic cerebral hypoperfusion: Sustained reduction in overall blood flow to the brain, as can occur with severe heart failure, cardiac arrhythmias, or carotid artery stenosis.

Key risk factors include:

• Hypertension: The single most significant modifiable risk factor. Chronic high blood pressure damages small blood vessels, accelerates atherosclerosis, and is the primary driver of subcortical small vessel disease. Midlife hypertension is particularly strongly linked to later-life cognitive impairment.
• Diabetes mellitus: Increases the risk of both large and small vessel disease and independently contributes to cognitive decline through neuroinflammation, insulin resistance in the brain, and microvascular damage.
• Atrial fibrillation: Irregular heart rhythm substantially increases the risk of embolic stroke and has been linked to cognitive decline even in the absence of clinically apparent stroke.
• Hyperlipidemia: Elevated cholesterol and lipids contribute to atherosclerosis of cerebral vessels.
• Smoking: Damages blood vessel walls, promotes atherosclerosis, and increases stroke risk.
• Obesity and physical inactivity: Contribute to cardiovascular disease burden through multiple pathways including hypertension, insulin resistance, and chronic inflammation.
• History of stroke or transient ischemic attack (TIA): A prior cerebrovascular event dramatically increases the risk of developing cognitive impairment. Approximately 20–30% of stroke survivors develop dementia within the first year after stroke.
• Age: Risk increases substantially with advancing age, particularly after age 65.
• Genetic factors: Rare hereditary conditions such as CADASIL (Cerebral Autosomal Dominant Arteriopathy with Subcortical Infarcts and Leukoencephalopathy), caused by mutations in the NOTCH3 gene, cause early-onset vascular dementia. The APOE ε4 allele, most commonly associated with Alzheimer's disease, also increases susceptibility to cerebral amyloid angiopathy.

A critical concept in this field is vascular cognitive reserve — the brain's ability to compensate for vascular damage. Factors such as higher educational attainment, intellectually stimulating activities, social engagement, and physical fitness appear to provide some buffer against the cognitive impact of cerebrovascular disease, though they cannot prevent it entirely.

Diagnosis of neurocognitive disorder due to vascular disease requires establishing both the presence of cognitive decline and a plausible cerebrovascular cause. The DSM-5-TR specifies that the following criteria must be met:

• Criteria are met for either major or mild neurocognitive disorder (i.e., documented cognitive decline from a previous level of functioning based on clinical assessment and standardized neuropsychological testing).
• The clinical features are consistent with a vascular etiology, as suggested by either: (1) onset of cognitive deficits temporally related to one or more cerebrovascular events, or (2) evidence of decline prominent in complex attention and frontal-executive functioning.
• There is evidence of cerebrovascular disease from history, physical examination, or neuroimaging sufficient to account for the neurocognitive deficits.
• The symptoms are not better explained by another brain disease or systemic disorder.

The diagnosis can be rated as probable (when supported by neuroimaging evidence of cerebrovascular disease, when cognitive decline is temporally related to a documented cerebrovascular event, or when there is both clinical and genetic evidence of vascular disease) or possible (when clinical criteria are met but neuroimaging is unavailable, or the temporal relationship is unclear).

The diagnostic evaluation typically includes:

• Comprehensive clinical history: A detailed account of cognitive changes, their onset and progression pattern, cardiovascular risk factors, prior strokes or TIAs, and functional impact. Collateral history from a family member or close informant is essential.
• Neurological examination: Assessment for focal neurological signs such as hemiparesis, gait abnormalities, visual field deficits, or pathological reflexes that suggest cerebrovascular damage.
• Neuropsychological testing: Standardized assessments of multiple cognitive domains — particularly attention, processing speed, executive function, memory, language, and visuospatial skills. The cognitive profile in vascular disease typically shows disproportionate impairment in executive function and processing speed relative to memory, distinguishing it from the amnestic profile typical of Alzheimer's disease.
• Neuroimaging: Brain imaging is a cornerstone of diagnosis.
  • Magnetic resonance imaging (MRI) is the preferred modality and can reveal cortical and subcortical infarcts, white matter hyperintensities (a marker of small vessel disease), lacunar infarcts, microbleeds, and brain atrophy.
  • Computed tomography (CT) can detect large infarcts and hemorrhages but is less sensitive to small vessel disease and white matter changes.
• Laboratory workup: Blood tests to identify and manage vascular risk factors (blood glucose, lipid panel, hemoglobin A1c, thyroid function, vitamin B12, complete blood count) and to rule out other causes of cognitive decline.
• Cardiovascular evaluation: May include electrocardiogram, echocardiogram, or carotid ultrasound to assess for atrial fibrillation, heart failure, or carotid stenosis.

An important diagnostic challenge is distinguishing pure vascular neurocognitive disorder from mixed dementia (vascular disease coexisting with Alzheimer's pathology). In clinical practice, mixed pathology is extremely common, particularly in older adults. Emerging biomarkers for Alzheimer's disease — including cerebrospinal fluid amyloid and tau levels, and amyloid PET imaging — are increasingly used to clarify whether Alzheimer's co-pathology is present.

There is currently no FDA-approved medication specifically for vascular neurocognitive disorder, and no treatment can reverse brain tissue that has been destroyed by vascular damage. However, a comprehensive management approach focused on preventing further cerebrovascular injury, managing symptoms, and maintaining quality of life can meaningfully slow progression and improve day-to-day functioning.

1. Aggressive Cardiovascular Risk Factor Management

This is the most critical component of treatment. Because vascular neurocognitive disorder is driven by cerebrovascular disease, controlling the underlying vascular risk factors is essential to prevent additional brain damage:

• Blood pressure control: Target blood pressure management as recommended by current cardiovascular guidelines. Effective antihypertensive treatment has been shown to reduce the risk of dementia and slow cognitive decline in individuals with cerebrovascular disease.
• Diabetes management: Maintaining appropriate glycemic control to reduce microvascular damage.
• Lipid management: Statin therapy where indicated to reduce atherosclerosis progression.
• Anticoagulation or antiplatelet therapy: For individuals with atrial fibrillation (anticoagulation) or atherosclerotic disease (antiplatelet agents) to prevent future strokes.
• Smoking cessation: Essential to reduce further vascular damage.

2. Pharmacological Approaches for Cognitive Symptoms

• Cholinesterase inhibitors (donepezil, galantamine, rivastigmine): Although developed for Alzheimer's disease, these medications have shown modest cognitive benefits in some trials of vascular dementia and are sometimes used off-label. The evidence is more consistent for mixed dementia (combined vascular and Alzheimer's pathology).
• Memantine: An NMDA receptor antagonist approved for moderate-to-severe Alzheimer's disease. Some studies have shown small benefits in vascular dementia, particularly in cognition and behavior, though results have been inconsistent.
• Notably, the effect sizes for these medications in vascular dementia are generally small, and they are not universally recommended by all clinical guidelines for pure vascular cognitive impairment.

3. Management of Neuropsychiatric Symptoms

• Depression: Antidepressant medications, particularly selective serotonin reuptake inhibitors (SSRIs), are commonly used. Depression is highly prevalent in vascular cognitive impairment and can significantly worsen cognitive and functional outcomes if untreated.
• Apathy: More difficult to treat pharmacologically; structured activities, behavioral activation, and environmental enrichment are first-line strategies.
• Agitation and behavioral disturbances: Non-pharmacological interventions (environmental modification, caregiver education, structured routines) are preferred. Antipsychotic medications carry significant risks in older adults with dementia, including increased cerebrovascular events and mortality, and should be used only for severe, refractory symptoms with careful monitoring.

4. Non-Pharmacological Interventions

• Physical exercise: Regular aerobic exercise improves cerebrovascular function, enhances cerebral blood flow, and has been associated with better cognitive outcomes in individuals with vascular cognitive impairment. Exercise programs should be tailored to the individual's physical abilities.
• Cognitive rehabilitation and stimulation: Structured cognitive training programs, particularly those targeting executive function and attention, show promise for maintaining or modestly improving cognitive abilities.
• Occupational therapy: Helps individuals develop compensatory strategies for daily activities and maintain functional independence as long as possible.
• Speech and language therapy: Beneficial for individuals with aphasia or communication difficulties following stroke.
• Caregiver support and education: Caring for someone with vascular dementia is demanding. Caregiver education about the disease, support groups, respite care, and counseling can reduce caregiver burden and improve outcomes for both the caregiver and the person with dementia.

The prognosis of vascular neurocognitive disorder is highly variable and depends on several factors, including the type and extent of cerebrovascular disease, the effectiveness of risk factor management, the presence of co-occurring neurodegenerative pathology, and the individual's overall health status and cognitive reserve.

Key prognostic considerations:

• Survival: On average, individuals with vascular dementia have a shorter life expectancy compared to age-matched controls and often compared to those with Alzheimer's disease. Median survival after diagnosis ranges from approximately 3 to 5 years, though this varies widely. Mortality is often driven by cardiovascular events (stroke, myocardial infarction) rather than the dementia itself.
• Cognitive trajectory: The course is heterogeneous. Some individuals experience a stepwise decline with periods of relative stability punctuated by sudden worsening (often linked to new cerebrovascular events). Others, particularly those with subcortical small vessel disease, show a more gradual, progressive decline. Still others remain relatively stable for extended periods, especially when vascular risk factors are well controlled.
• Functional decline: Loss of independence in activities of daily living tends to occur earlier in vascular dementia compared to Alzheimer's disease, partly due to the combination of cognitive and motor deficits (gait impairment, post-stroke weakness).
• Mixed pathology worsens prognosis: When vascular disease coexists with Alzheimer's pathology, cognitive decline tends to be more rapid and severe than with either condition alone.

Reasons for cautious optimism:

• Unlike most neurodegenerative dementias, vascular cognitive impairment has modifiable risk factors. Effective management of hypertension, diabetes, and other cardiovascular risks can meaningfully slow progression and prevent new cerebrovascular events.
• Some individuals with mild vascular neurocognitive disorder, particularly those who achieve excellent risk factor control, engage in regular physical exercise, and participate in cognitive stimulation, demonstrate relative stability or even modest improvement over time.
• Population-level data from several high-income countries suggest that age-specific dementia incidence — including vascular dementia — may be declining, likely due to improved cardiovascular care. This underscores the importance of prevention.

Advance care planning is an important conversation to initiate early in the disease course, while the individual can still meaningfully participate in decisions about future medical care, legal and financial matters, and living arrangements.

Vascular neurocognitive disorder exists within a broader landscape of conditions that affect cognition, brain vasculature, or both:

• Alzheimer's Disease: The most common cause of dementia. In clinical practice, Alzheimer's and vascular pathology frequently coexist (mixed dementia). The two conditions share several risk factors, including age, hypertension, diabetes, and the APOE ε4 allele.
• Mixed Dementia: The coexistence of vascular cerebrovascular disease with Alzheimer's disease pathology (and sometimes other neurodegenerative pathologies such as Lewy body disease). Autopsy studies suggest mixed pathology is more common than any single "pure" dementia subtype in older adults.
• Post-Stroke Cognitive Impairment: Cognitive decline that develops after a clinically evident stroke. This occurs in approximately 20–30% of stroke survivors and may meet criteria for vascular neurocognitive disorder depending on its severity and persistence.
• Frontotemporal Dementia: A group of neurodegenerative disorders affecting the frontal and temporal lobes. The executive dysfunction and behavioral changes seen in vascular neurocognitive disorder can overlap with frontotemporal dementia, making differential diagnosis important.
• Lewy Body Dementia: Another neurodegenerative dementia that can coexist with vascular pathology. Features such as fluctuating cognition, visual hallucinations, and parkinsonism help distinguish it from primarily vascular etiologies.
• CADASIL: A rare hereditary form of cerebral small vessel disease caused by NOTCH3 gene mutations, leading to recurrent strokes, migraine with aura, mood disturbances, and progressive dementia, often beginning in midlife.
• Major Depressive Disorder: Depression is both a risk factor for and a frequent comorbidity of vascular cognitive impairment. The concept of "vascular depression" — late-onset depression associated with white matter lesions and executive dysfunction — highlights the overlap between cerebrovascular disease and mood disorders.

Early identification of vascular cognitive impairment is crucial because — unlike most neurodegenerative dementias — the underlying vascular risk factors are treatable, and further brain damage is potentially preventable. Seek professional evaluation if you or someone close to you notices any of the following:

• Sudden changes in thinking or behavior — especially difficulty with planning, organizing, decision-making, or problem-solving that develops abruptly or over a short period
• Cognitive changes following a stroke or TIA — even if physical recovery seems adequate, cognitive effects may be significant and warrant formal assessment
• Noticeable slowing of thinking — processing information more slowly, struggling to keep up with conversations, or difficulty multitasking
• Gait changes — new-onset unsteadiness, shuffling gait, or frequent falls, particularly in combination with cognitive changes
• Personality or mood changes — persistent apathy, withdrawal from social activities, or new-onset depression, especially in someone with cardiovascular risk factors
• Memory difficulties — forgetting appointments, repeating questions, or struggling with tasks that were previously routine
• Difficulty managing daily responsibilities — trouble paying bills, managing medications, cooking, or navigating familiar routes

The appropriate starting point for evaluation is a primary care physician, who can conduct an initial cognitive screening, review cardiovascular risk factors, order basic laboratory tests and neuroimaging, and provide referrals as needed. A neurologist or geriatric psychiatrist can provide specialized diagnostic evaluation, and a neuropsychologist can administer comprehensive cognitive testing to characterize the pattern and severity of impairment.

Seek emergency medical attention immediately if someone experiences sudden onset of confusion, slurred speech, weakness on one side of the body, vision changes, severe headache, or difficulty walking — these may indicate an acute stroke, which is a medical emergency where rapid treatment can prevent or minimize brain damage.

Remember: cognitive changes should never be dismissed as "just normal aging." While some modest cognitive changes occur with healthy aging, significant or sudden decline in thinking abilities always warrants professional evaluation. The earlier vascular cognitive impairment is identified, the more effectively its progression can be slowed through risk factor management and comprehensive care.